Human medicines European public assessment report (EPAR): Kromeya, adalimumab, Arthritis, Rheumatoid,Arthritis, Juvenile Rheumatoid,Psoriasis,Arthritis, Psoriatic,Spondylitis, Ankylosing,Uveitis,Colitis, Ulcerative,Crohn Disease, Date of authorisation: 02/04/2019, Status: Authorised

2019 ◽  
Author(s):  
Sign in / Sign up

Export Citation Format

Share Document